BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Clinical trial NCT03914742 · COMPLETED

Trial details

NCT number: NCT03914742
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

IDH1 Mutation IDH2 Mutation Recurrent Glioblastoma Recurrent WHO Grade II Glioma Recurrent WHO Grade III Glioma

Start date: 2020-02-16
Primary completion: 2023-10-31
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.